Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa

Current Eye Research

Volumn 34, Issue 3, 2009, Pages 231-237

  Yuzbasioglu, Erdal ^a   Artunay, Ozgur ^a   Rasier, Rifat ^a   Sengul, Alper ^a   Bahcecioglu, Halil ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Avastin; Intravitreal bevacizumab; Macular edema; Retinal dystrophies; Retinitis pigmentosa

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; RETINITIS PIGMENTOSA; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINITIS PIGMENTOSA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 62249123896     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802710692     Document Type: Article

References (30)

1. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;101:687-693.
2. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmologica Scand. 2005;83:248-251.
3. Fishman GA, Glenn AM, Gilberd LD. Rebound of macular oedema with continued use of methosolamide in patients with retinitis pigmentosa. Arch Ophthalmol. 1993;111:1640-1646.
4. Fishman GA, Maggiano JM, Fishman M. Focal lesions seen in retinitis pigmentosa. Arch Ophthalmol. 1977;95:1993-1996.
5. Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2005;46:3349-3354.
6. Wolfensberger TJ. The historical discovery of macular oedema. Documenta Ophthalmologica 1999;97:207-216.
7. Nuel JP. Alterations in macula lutca: perifoveal macular edema. Arch d'Ophthalmol. 1896;16:145-181.
8. Grover S, Apuskin MA, Fishman GA. Topical dorsolamide for the treatment of cystoidmacular edema in patientswith retinitis pigmentosa. Am J Ophthalmol. 2006;141:850-858.
9. Fishman GA, Gilberd LD, Fiscella RG, et al. Acetalazomide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107:1445-1452.
10. Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 1999;97:387-397.
11. Giusti C, Forte R, Vingolo EM. Deflazacort treatment of cystoid macular edema in patients affected by retinitis pigmentosa: A pilot study. Eur Rev Med Pharmacol Sci. 2002;6:1-8.
12. Newsome DA, Blackharski PA. Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1987;15;103:161-166.
13. Kim JE. Intravitreal triamcinolone acetonide for treatment of cystoid macular edema associated with retinitis pigmentosa. Retina. 2006;26:1094-1096.
14. Scorolli L, Morara M, Meduri A, Reggiani LB, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 2007;125:759-764.
15. Weiner JM. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman AG, Rall TW, Nies AS, Taylor P, ed. The Pharmacological Basis of Therapeutics, 8th ed. New York: MacMillan; 1990:716-718.
16. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology. 1981;88:261-265.
17. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
18. Itturalde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina. 2006;26:279-284.
19. Pedersen R, Soliman W, Lund-Anderson H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand. 2007;85:526-533.
20. Rosenfeld PJ, Mosfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imag. 2005;36:331-335.
21. Melo GB, Farah ME, Aggio FB. Intravitreal injection of bevacizumab for cystoidmacular edema in retinitis pigmentosa. Acta Ophthalmol Scand. 2007;85:461-463.
22. Barki SJ, Snyher MR, Reid JM, Pulido SJ, Singh RJ. Pharmacokinetics of intravitreal Bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
23. Cox SN, Hay E, Bird AC. Treatment of choronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190-1195.
24. Swante P, Peter H, Sylvie J, Focke Z, Heika F, Karl UB, Ulrich S. Ultrastructural findings in primate eye after intravitreal injection of bevacimuzab. Am J Ophthalmol. 2007;143:995-1002.
25. Vinores SA, Youssri AI, Luna JD, Chen Y-S, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
26. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505-517.
27. Vinores SA, Chan C-C, Vinores MA, Matteson DM, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor β (TGF β) in experimental autoimmune uveoretinitis: Upregulation of VEGF without neovascularization. J Neuroimmunol. 1998;89:43-50.
28. Heiduschka P, Fiets H, Hofmeister S, Schultheiss S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2813-2823.
29. Browning D, Fraser C, Propst B. The variation in optical coherence tomography3/4measuredmacular thickness in diabetic eyes without clinical macular edema. Am J Ophthalmol. 2008;145:889-893.
30. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.